{
}
China’s President Xi Jinping urged multinational CEOs to safeguard global trade and supply chains amid rising US tariffs, emphasizing the need for cooperation to stabilize the economy. The meeting, attended by around 40 executives, highlighted concerns over tightening regulations and foreign investment challenges in China. Xi noted the significant contributions of foreign enterprises to China's economy, while reiterating the mutually beneficial nature of China-US trade relations.
Goldman Sachs has raised its price target for AstraZeneca shares to £151.30, maintaining a Conviction Buy rating, citing an 18% revenue growth and potential in the oral PCSK9 inhibitor market with AZD0780. The anticipated Phase 2 PURSUIT trial data, due on March 31, 2025, is expected to significantly impact the competitive landscape. AstraZeneca is also investing $2.5 billion in a new R&D center in Beijing, enhancing its presence in China and focusing on early-stage research and clinical development.
UBS has maintained a "Buy" rating for AstraZeneca with a target price of 14,200 pence. Analyst Matthew Weston advised caution regarding the Calypso study results for Enebo, a treatment for hypothyroidism, noting the absence of a "clinically significant" designation for the primary endpoint and lack of independent expert commentary, suggesting unmet competitive expectations.
UBS has upgraded AstraZeneca from "Neutral" to "Buy," raising its price target from 11,500 to 14,200 pence. Analyst Matthew Weston highlighted the company's promising pipeline, projecting an additional USD 17.6 billion in sales by 2030, contingent on successful trial outcomes for seven key drugs in 2025. Shares rose by 1.37% to GBP 119.64 following the announcement.
UBS has upgraded AstraZeneca to a 'buy' rating, highlighting the company's "sector-leading" drug pipeline and strong growth potential. The firm ranks second among global pharma peers, with a 12-month price target of 14,200p, following a forecast-beating revenue surge of 21% for 2024. AstraZeneca's shares rose nearly 2% to 11,988.0p.
UBS has adjusted its ratings on key European pharmaceutical companies, downgrading Novartis to Neutral due to concerns over patent expirations and a limited pipeline, while upgrading Roche to Buy, citing strong growth prospects and a robust pipeline. AstraZeneca also received a Buy upgrade, driven by its sector-leading pipeline potential, with both companies seeing significant increases in their price targets.
UBS has downgraded Novartis to Neutral from Buy, citing concerns over patent expirations and a limited pipeline, with EBIT growth expected to decline significantly in 2025. In contrast, Roche and AstraZeneca received upgrades to Buy, driven by strong pipeline prospects and revenue growth potential, with Roche's price target raised to CHF 338 and AstraZeneca's to £142.
UBS has upgraded AstraZeneca's stock rating from Neutral to Buy, increasing the target price from 11,500 pence to 14,200 pence, indicating a 22% upside potential. For the full year, AstraZeneca reported total sales of $54 billion, an 18% increase, with EPS of $4.54. The company anticipates a high single-digit percentage rise in total sales and a low double-digit percentage increase in core EPS for 2025.
AstraZeneca has received an upgrade to a "buy" rating from UBS, as reported by Cercle Finance. BOURSORAMA, acting solely as a distribution channel, emphasizes that it has not influenced the analysis, which is provided for informational purposes only and carries no contractual value. The institution maintains a conflict of interest management policy to ensure objectivity in its investment recommendations.
AstraZeneca has been upgraded to a Buy rating from Neutral by UBS, signaling a positive shift in the investment outlook for the company. This upgrade reflects increased confidence in AstraZeneca's performance and potential growth in the market.
AstraZeneca PLC
Companies
| Symbol | AZN |
| Name | AstraZeneca PLC |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Pharmaceuticals |
| Market | NASDAQ Global Select |
| Country | United Kingdom |
| State | |
| City | Cambridge |
| Zipcode | CB2 0AA |
| Website | http://www.astrazeneca.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
China's Xi urges CEOs to safeguard trade amid looming US tariffs
United States Dollar
Toyota Motor Corp
Hitachi, Ltd.
AstraZeneca PLC
Standard Chartered PLC
Mercedes-Benz Group AG
FedEx Corp
SK hynix Inc.
SAU
CHN
USA
Georges Elhedery
Kwak Noh-Jung
Toshiaki Higashihara
Raj Subramaniam
Xi Jinping
Amin Nasser
Ola Källenius
Show more
13:01 28.03.2025
Goldman Sachs raises AstraZeneca target amid promising drug development and expansion
08:50 28.03.2025
ubs maintains buy rating for astrazeneca amid cautious study results
12:47 17.03.2025
ubs upgrades astrazeneca to buy citing strong sales potential through 2030
13:25 13.02.2025
ubs upgrades astrazeneca to buy citing strong drug pipeline and growth potential
13:20 13.02.2025
ubs adjusts ratings on european pharma stocks novartis downgraded roche upgraded
13:14 13.02.2025
ubs downgrades novartis while upgrading roche and astrazeneca ratings
British Pound Sterling
Swiss Franc
AstraZeneca PLC
Novartis AG
Hoffmann-La Roche AG
GBR
CHE
Show more
13:01 13.02.2025
ubs upgrades astrazeneca to buy with significant target price increase
12:46 13.02.2025
ubs upgrades astrazeneca shares to buy rating
12:46 13.02.2025
AstraZeneca receives buy rating upgrade from UBS analysts
10:45 13.02.2025
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Banking Regulations
Finance Mergers & Acquisitions
Global Financial Events
Retail and Consumer Goods
Central Bank Actions
GDP Growth & Recession Forecasts
CEO Changes
Global Trade Developments
Financial Scams and Security
Industry Mergers & Acquisitions
Market Analysis and Predictions
Inflation and Monetary Impact
Government Policies
Government Economic Policies
Supply Chain Management
Domestic Politics
Workplace Trends
Countries:
Companies:
The Goldman Sachs Group, Inc.
JPMorgan Chase & Co.
Tesla, Inc.
Apple Inc.
Bank of America Corporation
Barclays PLC
Wells Fargo & Company
Citigroup Inc.
Deutsche Bank Money Market PP
Morgan Stanley
Huawei Technologies CO. Ltd.
Lloyds Banking Group plc
Credit Suisse Strategic Income I
AXA SA
Safran SA
Banco Santander, S.A.
Novartis AG
Swiss Re AG
Beazley plc
UBS AG
Currencies:
United States Dollar
Euro
Chinese Yuan
British Pound Sterling
Swiss Franc
Japanese Yen
Indian Rupee
Russian Ruble
Canadian Dollar
Australian Dollar
United Arab Emirates Dirham
Saudi Riyal
Danish Krone
Offshore Chinese Yuan
Mexican Peso
Indonesian Rupiah
South Korean Won
Malaysian Ringgit
Vietnamese Đồng
New Zealand Dollar
People: